Newsletter-Archiv

Access preclinical news from InnoSer labs

Aktuelles direkt in Ihren Posteingang

Kontaktieren Sie unsere Forschungsexperten

Neurology Newsletters

June 2026 newsletter – Cognitive profiling in the APP[V717I]xTau[P301S] mouse model

May 2026 newsletter – Translational Neuroscience: Comprehensive longitudinal profiling of the Tau[P301S] female vs male mice

April 2026 newsletter – Clinically relevant biomarker panels for comprehensive efficacy studies in Alzheimer’s Disease mouse models.

March 2026 newsletter – HTT1a and HTTexon1 Huntington’s disease – A new therapeutic target explored in the zQ175 mouse model

January 2026 newsletter -Modelling TDP-43 proteinopathy and motor neuron disease pathophysiology in mouse models

November 2025 newsletter –Neurofilament light chain (NfL) in plasma and CSF: A translational biomarker for neurodegeneration in InnoSer’s neurology mouse models

October 2025 newsletter – New insights into TDP-43 mouse model pathology

February 2025 newsletter – Gene Therapy Delivery Optimization

December 2024 newsletter – MDX Mouse Model Validation Data

August 2024 newsletter – Phenotyping of a C3-PMP22 Mouse Model of CMT1A

July 2024 newsletter – Characterization of a transgenic TDP-43 Mouse Model

May 2024 newsletter – Characterization of a Spinal Cord Injury (SCI) Mouse Model

April 2024 newsletter – Relevant Pharmaco-EEG in vivo data (Baclofen, Fenfluramine)

February 2024 newsletter – How to obtain the most value out of your neurodegenerative disease research models?

January 2024 newsletter – eIF2B Modulators in Vanishing White Matter

December 2023 newsletter – Repeated EEG Measurements for Longitudinal Efficacy Assessment of Novel AEDs in Epilepsy Research Model

November 2023 newsletter – Cognitive Readouts to Enhance the Efficacy Testing of Metabolic Compounds

October 2023 newsletter – Amyloid beta-induced neuroinflammation in Alzheimer’s disease models

September 2023 newsletter – EEG Recording in the Epileptic Encephalopathy Model

July 2023 newsletter – Auditory Event-Related Potentials EEG-Recording in Fmr1 KO mice

General Research InnoSer preclinical CRO research

General Research Newsletters

May 2026 newsletter – Total kidney volume (TKV) as a translationally relevant, non-invasive disease progression readout

April 2026 newsletter – Knocking out Pkd1 in the P40 mouse model enables extended dosing windows and long-term efficacy studies

March 2026 newsletter – InnoSer Presents New Data at the 8th CKD Summit 2026: Advancing Preclinical Models for ADPKD Research

February 2025 newsletter – Targeted Gene Therapy Preclinical Testing Approaches in the ADPKD Mouse Model

November 2024 newsletter – Therapeutic Targets for ADPKD

August 2024 newsletter – Glomerular filtration rate (GFR) in the ADPKD Mouse Model

July 2024 newsletter – Effect of Salsalte on ADPKD Progresion in ADPKD Mouse Model

April 2024 newsletter – Salsalate ameliorates disease progression in ADPKD mouse model

March 2024 newsletter – Assessment of Disease Progression in the ADPKD Mouse Model

February 2024 newsletter – Latest cardiovascular and metabolic research news

February 2024 newsletter – PK/PD and Tolerability Testing in the ADPKD Mouse Model

January 2024 newsletter – The Application of Cystic Index in the ADPKD Mouse Model

December 2023 newsletter – How to ensure that you are working with translationally relevant kidney disease research models?

November 2023 newsletter – Validated Trasdermal GFR Measurement in Kidney Disease Models

Oncology Newsletters

March 2026 newsletter – Personalized Lymphoma CDX mouse models for preclinical oncology

February 2025 newsletter – Multiplex Cytokine and Immune Cell Profiling in Immuno-Oncology Research

December 2024 newsletter – Pancreatic Cancer PDX Models

August 2024 newsletter – RENCA Mouse Model of Renal Cancer

May 2024 newsletter – Tumor microenvironment (TME) multiplex immunophenotyping analyses

March 2024 newsletter – Relevant in vivo studies and in vitro immuno-oncology assays

February 2024 newsletter – In Vivo Tumorigenicity Testing to Evaluate Your Therapeutics’ Safety

January 2024 newsletter – Getting the Most out of Bioluminescent Imaging for Your Research

December 2023 newsletter – Peritoneal Cancer Index to Evaluate Efficacy in a Peritoneal Cancer Model

November 2023 newsletter – Validated Delayed-type Hypersensitivity Assay in Wild Type or Humanized Mice

October 2023 newsletter – Immunophenotyping to Evaluate Immune Therapy’s Success

Seien Sie als Erster informiert – erhalten Sie diese Neuigkeiten direkt in Ihren Posteingang

InnoSer bietet eine Vielzahl validierter In-vitro- und In-vivo-Plattformen für die effiziente Entwicklung neuartiger Therapeutika. Wenn Sie weitere Informationen benötigen, können Sie sich gerne an uns wenden – wir melden uns innerhalb weniger Tage bei Ihnen.

Wir veröffentlichen monatlich einen Newsletter aus unseren InnoSer-Labors mit wissenschaftlichen Einblicken in unsere Forschungsdienstleistungen. Um die Neuigkeiten direkt in Ihren Posteingang zu erhalten, melden Sie sich bitte hier an.

Anmelden – Neuigkeiten aus der Neurologie

Anmelden – Nachrichten aus der Onkologie

Ein Projekt besprechen

Unverbindlich – Los geht’s

info@innoserlaboratories.com

Schnellzugriff

CRO-Dienstleistungen im Bereich Neurologie

Dienstleistungen von CROs im Bereich der Onkologie

CRO-Dienstleistungen im Bereich Immunologie

CRO-Dienstleistungen im Bereich Nephrologie

Verhaltenstests

Pathologische Dienstleistungen

Koloniebewirtschaftung

Vermietung von Terrarien

Über

Über InnoSer

Blog

Newsletter-Archiv

Wissenschaftlicher Beirat

Datenschutzerklärung

Stellenangebote